Status:

COMPLETED

Isolating Mechanisms in the Treatment of Borderline Personality Disorder

Lead Sponsor:

Boston University Charles River Campus

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

Borderline Personality Disorder

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Borderline personality disorder (BPD) is a commonly occurring, severe, and costly condition that interferes greatly with quality of life. Considerable comorbidity with other disorders and existing mul...

Detailed Description

Borderline personality disorder (BPD) is a commonly occurring, severe, and costly condition for which treatment efforts have been hindered by several factors. First, extant treatments for BPD are long...

Eligibility Criteria

Inclusion

  • Diagnostic and Statistical Manual (5th Edition; DSM-5) diagnosis of borderline personality disorder;
  • willing to maintain a stable dose on prescribed psychotropic medication throughout the study duration. This avoids problems with reluctance to discontinue or difficulty with discontinuing, and also the confounding of outcomes from initiation of medication during treatment; this procedure is a longstanding practice at the Center for Anxiety and Related Disorders (CARD) at Boston University for treatment outcome research. Additionally, participants must be
  • fluent in English.

Exclusion

  • In order to maximize generalizability, exclusion criteria are based solely on the well-being of the participant and will consist primarily of conditions that would require prioritization for immediate treatment (e.g., severe suicidality or substance dependence). These include:
  • Current DSM-5 diagnoses of bipolar disorder, schizophrenia, schizoaffective disorder, or organic mental disorder;
  • Clear and current suicidal risk (intent);
  • Current or recent (within 3 months) history of drug dependence;
  • Willingness to refrain from additional psychosocial treatment across the course of the study; and
  • has access to own smartphone.

Key Trial Info

Start Date :

October 15 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 30 2020

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT03408860

Start Date

October 15 2017

End Date

August 30 2020

Last Update

November 16 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Boston University Center for Anxiety and Related Disorders

Boston, Massachusetts, United States, 02215